These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 8971292)

  • 1. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
    Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
    Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
    Mahmud N; Weir DG; Kelleher D
    Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
    Ewe K; Becker K; Ueberschaer B
    Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.
    Karamanolis DG; Papatheodoridis GV; Xourgias V
    Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1083-8. PubMed ID: 8944370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
    Støa-Birketvedt G; Florholmen J
    Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
    Staerk Laursen L; Stokholm M; Bukhave K; Rask-Madsen J; Lauritsen K
    Gut; 1990 Nov; 31(11):1271-6. PubMed ID: 2253912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis.
    Birketvedt GS; Berg KJ; Fausa O; Florholmen J
    Inflamm Bowel Dis; 2000 Nov; 6(4):275-9. PubMed ID: 11149559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation.
    Gionchetti P; Campieri M; Venturi A; Rizzello F; Ferretti M; Brignola C; Miglioli M
    Aliment Pharmacol Ther; 1996 Aug; 10(4):601-5. PubMed ID: 8853765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
    Schroeder KW
    Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.
    Courtney MG; Nunes DP; Bergin CF; O'Driscoll M; Trimble V; Keeling PW; Weir DG
    Lancet; 1992 May; 339(8804):1279-81. PubMed ID: 1349676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers.
    Rijk MC; van Hogezand RA; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1989 Dec; 24(10):1179-85. PubMed ID: 2574905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
    Rijk MC; van Schaik A; van Tongeren JH
    Scand J Gastroenterol Suppl; 1988; 148():54-9. PubMed ID: 2906478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.
    Rao SS; Cann PA; Holdsworth CD
    Scand J Gastroenterol; 1987 Apr; 22(3):332-6. PubMed ID: 2884724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
    Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.
    Dew MJ; Ebden P; Kidwai NS; Lee G; Evans BK; Rhodes J
    Br J Clin Pharmacol; 1984 Apr; 17(4):474-6. PubMed ID: 6144318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea.
    Rijk MC; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1992 Oct; 27(10):863-8. PubMed ID: 1359629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
    Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
    Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mesalazine enema for ulcerative colitis.
    Drug Ther Bull; 1994 May; 32(5):38-9. PubMed ID: 7635028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?
    Nakshabendi IM; Duncan A; Russell RI
    Postgrad Med J; 1992 Mar; 68(797):189-91. PubMed ID: 1350343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
    Sandborn WJ; Hanauer SB
    Aliment Pharmacol Ther; 2003 Jan; 17(1):29-42. PubMed ID: 12492730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.